Drug
Rilonacept
Rilonacept: highest development phase Phase 3, developed by Kiniksa Pharmaceuticals, Regeneron. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Kiniksa Pharmaceuticals, Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rilonacept NCT00856206 | Phase 3 | Gout |
| Rilonacept NCT03737110 | Phase 3 | Recurrent Pericarditis |
Latest
No recent events.
Follow Rilonacept on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.